November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Niklas Klümper: New study on JAMA Oncology about long-term risks of prostate cancer treatments
Nov 12, 2024, 09:06

Niklas Klümper: New study on JAMA Oncology about long-term risks of prostate cancer treatments

Niklas Klümper, Senior Urology Consultant at the University Medical Center Bonn, shared a post on X about a recent paper by Joseph Unger, Associate Professor in the cancer prevention program at Fred Hutchinson Cancer Research Center:

New study on JAMA Oncology highlights long-term risks of prostate cancer treatments!

Patients undergoing prostatectomy or radiotherapy face significant risks of urinary, sexual, and radiation-related complications. Notably, radiation therapy triples bladder cancer risk and increases radiation-specific complications dramatically.

Findings underscore the need for careful patient counseling on risks vs. benefits before PCA treatment decisions! Active surveillance needs to be carefully discussed in low-risk settings to spare toxicity!”

Oliver Hahn, Urologist at University Medical Center Göttingen, shared this post, adding:

“… Which underlines again one thing: urological oncology simply does not work without functional urology – and patients need to be made aware that there is more than just remission status to be taken into account. Very important evidence shared by Niklas Klümper.”

“Long-Term Adverse Effects and Complications After Prostate Cancer Treatment”

Authors: Joseph Unger, Cathee Till, Catherine Tangen, Howard Parnes, Ian Thompson et al.

Niklas Klümper: New study on JAMA Oncology about long-term risks of prostate cancer treatments

More posts featuring Niklas Klümper.

Niklas Klümper, MD, is a senior urology consultant specializing in genitourinary (GU) oncology and an advanced clinician-scientist at the University Medical Center Bonn (UKB), supported by the BMBF-funded ACCENT program. He leads a translational uro-oncology research group that bridges the Department of Urology and the Institute of Experimental Oncology. His research focuses on improving treatment response predictions for targeted therapies, developing personalized treatment strategies, and conducting clinical trials to enhance outcomes for patients with uro-oncological diseases.